So just to level set, the RESTORE study began in March of 2020, obviously coinciding with when the pandemic started. What we put out this October is that we've had about 27% of participants discontinue in this study. So being open label and the fact that these participants are having to travel to the clinical trial sites once a month to pick up their medication because it is a schedule one until the point of approval. We're not surprised by that rate of discontinuation. In fact, I could have understood if it were higher with the requirement to travel to those sites on a monthly basis.

Nov 9, 2022 / receipt, needs a key / Jen, other | earnings call 2022-11-09 | transcript fb770001-305a-49f5-8697-8c6b0e793489 | chars 31092-31683 | segment 31